Business Context and Reporting Period
This Form 8-K Current Report is filed by Synaptogenix, Inc. (SNPX) for the period ending June 9, 2025. The filing details a private placement of Series D convertible preferred stock, amendments to existing Series C securities, new consulting agreements, and significant changes to the company's executive leadership. The company is an emerging growth company focused on biotechnology and has announced a new cryptocurrency treasury strategy.
Key Financial Metrics and Capital Structure
- Private Placement Proceeds: Expected aggregate gross proceeds of $5.5 million from the sale of 5,500 shares of Series D Convertible Preferred Stock.
- Conversion Terms: Preferred stock is convertible into up to 1,833,333 shares of common stock at an initial conversion price of $3.00 per share.
- Warrant Issuance: Investors received warrants to purchase up to 1,833,333 shares of common stock at an exercise price of $3.00 per share.
- Dividend Obligations: Series D Preferred Stock carries a 5% annual dividend compounded quarterly, increasing to 15% upon a "Triggering Event."
- Redemption Schedule: The company must redeem the Preferred Stock in equal quarterly installments commencing September 30, 2025, at 107% of the installment amount.
- Placement Agent Fees: A cash fee of 7.0% of gross proceeds and warrants equal to 3.0% of the convertible shares.
- Executive Compensation Changes:
- Dr. Daniel L. Alkon (Consultant): Base salary reduced to $12,500/month.
- Dr. Alan J. Tuchman (CMO): Base salary reduced to $7,500/month.
- Joshua Silverman (Executive Chairman): New monthly salary of $30,000.
Material Changes Versus Prior Period
- Leadership Restructuring: Dr. Alan J. Tuchman resigned as CEO and Director to become Chief Medical Officer. Dr. Daniel L. Alkon resigned as Chief Science Officer and Director to become a consultant. Joshua Silverman was appointed Executive Chairman.
- Capital Structure: Issuance of new Series D Preferred Stock and warrants, alongside amendments to Series C Preferred Stock and Warrants to modify redemption rights and volatility calculation inputs.
- Strategic Pivot: Announcement of a differentiated cryptocurrency treasury strategy to acquire $10 million of Bittensor TAO tokens as a treasury reserve asset.
- Consulting Agreements: Engagement of James Altucher and Z-List Media for crypto portfolio management and investor relations, compensated via tranching warrants totaling 1,200,000 shares.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds from the $5.5 million private placement will be used for general corporate purposes, working capital, and the acquisition of Bittensor TAO tokens.
- Stockholder Approval: The company must seek stockholder approval for the issuance of shares exceeding 19.99% of outstanding common stock by September 1, 2025, to fully settle conversions.
- Registration Rights: The company is obligated to file a resale registration statement covering 200% of conversion and warrant shares within 30 days of the closing, with liquidated damages for failure to comply.
- Triggering Events: Failure to file registration statements or pay dividends may trigger a 15% dividend rate and mandatory redemption of Preferred Stock at a premium.
- Market Risk: The company is entering the cryptocurrency market with a significant treasury allocation ($10 million target), introducing volatility risks associated with digital assets.
Investor Verification Checklist
- Verify the closing date of the private placement (expected June 10, 2025) and confirmation of the $5.5 million gross proceeds.
- Confirm the timeline for the stockholder vote required to approve the issuance of shares beyond the 19.99% Nasdaq limit (deadline: September 1, 2025).
- Review the specific terms of the Series C Certificate of Amendment regarding the elimination of redemption rights for Series C investors.
- Monitor the execution of the $10 million Bittensor TAO acquisition and the appointment of the treasury manager required to unlock the second tranche of the Altucher warrants.
- Assess the impact of the new quarterly redemption obligations (starting September 30, 2025) on the company's liquidity position.